Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ESSA Pharmaceuticals
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Male 18 years of age or older.
Histologically, pathologically, or cytologically confirmed prostate cancer without small cell features.
Evidence of castration-resistant prostate cancer (CRPC).
Presence of metastatic disease at study entry documented by 1 or more bone lesions on bone scan or by soft tissue disease observed by CT/MRI.
Limited further treatment options available known to confer clinical benefit in this disease setting from the perspective of the treating physician. Specifically, patients must have progressed on at least 2, but not more than 3, prior approved systemic therapies for mCRPC which include at least one, but not more than 2, second generation anti-androgen drug.
Patients may have received prior docetaxel for mCSPC or mCRPC but must not have had disease progression during, or within 6 months of completing chemotherapy. Only one line of prior chemotherapy is allowed.
Evidence of progressive disease defined as 1 or more Prostate Cancer Working Group 3 (PCWG3) criteria.
The patient must have recovered from toxicities related to any prior treatments.
Castrate at screening.
Patients receiving bisphosphonates or other approved bone-targeting therapy must be on a stable dose for at least 4 weeks prior to the start of study drug.
Demonstrate adequate organ function.
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
Patients are eligible to enroll in this cohort if they meet the clinical criteria for receiving AAP as standard of care treatment as per label (i.e., high-risk mHSPC or mCRPC).
Part B/Cohort 2 (Window of Opportunity with clinical endpoints followed by combination with Apalutamide)
Male 18 years of age or older.
Histologically, pathologically, or cytologically confirmed prostate cancer without small cell features.
Evidence of castration-resistant prostate cancer (CRPC).
Patients who received a first generation anti-androgen as part of an initial combined androgen blockade therapy or as second-line hormonal therapy must show continuing disease (PSA) progression off the anti-androgen for at least 4 weeks prior to enrollment.
At least 4 weeks must have elapsed from the use of 5-α reductase inhibitors, estrogens, and any other anti-cancer therapy prior to enrollment.
At least 4 weeks must have elapsed from major surgery or radiation therapy prior to enrollment.
The patient must have recovered from toxicities related to any prior treatments.
Castrate at screening.
Demonstrate adequate organ function.
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
You may not be if
Biologic anti-cancer therapy or a cytotoxic chemotherapy within 4 weeks prior to the start of study drug.
Use of hormonal agents with anti-tumor activity against prostate cancer within 4 weeks prior to the start of study drug.
Any lutamides or abiraterone within 14 days or 5 half-lives, whichever is longer prior to start of study drug.
Use of radium-223 dichloride or other radioligand/radiopharmaceutical within 28 days prior to the start of study drug.
Received limited-field palliative bone radiotherapy \>5 fractions and/or any radiotherapy within 2 weeks prior to the start of study drug.
Received a blood transfusion within 28 days of screening.
Received prior chemotherapy (for Part 1b Cohort A only).
Known intra-cerebral disease or brain metastasis unless adequately treated and stable for the last 4 weeks before enrollment.
Spinal cord compression.
Diagnosis of another invasive malignancy within the previous 3 years other than curatively treated non-melanomatous skin cancer or superficial urothelial carcinoma.
Gastrointestinal disorder affecting absorption.
Significant cardiovascular disease.
Concurrent disease or any clinically significant abnormality.
Use of strong inducers of CYP3A within 14 days of the first dose of study drug.
Any prior treatment with chemotherapy.
Use of concomitant CYP2D6 substrates with narrow therapeutic index.
Known allergies, hypersensitivity, or intolerance to the excipients of AA (refer to AA Investigator's Brochure \[IB\] or package inserts as appropriate).
Part B Cohort 2 (Window of Opportunity with clinical endpoints followed by combination with Apalutamide)
Presence of distant metastases, including visceral, nodal and bones involvement. Exception: pelvic lymph nodes \< 2 cm in short axis (N1) located below the iliac bifurcation are allowed.
Symptomatic loco-regional disease requiring medical intervention, such as moderate or severe urinary obstruction or hydronephrosis due to primary tumor.
Prior treatment with second generation anti-androgens.
Prior treatment with CYP17 inhibitors.
Prior treatment with radiopharmaceutical agents, immunotherapy, or any other investigational agent for nmCRPC.
Prior chemotherapy.
History or evidence of: prior malignancy (other than adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or any other cancer in situ currently in complete remission) within 3 years prior to enrollment; severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events; uncontrolled hypertension.
Gastrointestinal disorder affecting absorption.
Use of strong inducers of CYP3A within 14 days of the first dose of study drug.
Clareo Health | Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer
